Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 13Urogenital Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Neoplasms 2Genital Neoplasms, Male 2Breast Neoplasms 2Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Male Urogenital Diseases 1Genital Diseases, Male 1Castrate-resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Advanced Prostate Cancer 1Adenocarcinoma 1

Interventions

Abiraterone Acetate 2onapristone 1olaparib 1gedatolisib 1darolutamide 1abiraterone 1Radiotherapy 1Pluvicto 1Nivolumab 1Lutetium-177 1Lutetium 1EPI-506 1Brachytherapy 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Diseases × Abiraterone Acetate × Clear all
NCT06785636 2026-04-24

P300

Pathos AI, Inc.

Phase 1/2 Recruiting
252 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT02049190 2015-06-24

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Arno Therapeutics

Phase 1/2 Unknown
75 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡